Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 10:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 52 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Inspra (eplerenone) Clear all
Completed Phase 3 Interventional

The Long-term Study to Evaluate the Safety of Eplerenone in the Treatment of Hypertension in Children Aged 6 to 16 Years

NCT00147615
View directory record Official record
Conditions
Hypertension
Interventions
Eplerenone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
6 Years to 16 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
7
States / cities
Los Angeles, California • Park Ridge, Illinois • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Sep 23, 2026, 10:32 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Eplerenone and IOP in Healthy Adults

NCT07795762
View directory record Official record
Conditions
Intraocular Pressure (IOP), Healthy Adult
Interventions
Eplerenone, Microcrystalline Cellulose NF (placebo)
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 23, 2026, 10:32 AM EDT
Completed Phase 4 Interventional

The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure

NCT00082589
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
Eplerenone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
21 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
53
States / cities
Castro Valley, California • San Diego, California • Santa Rosa, California + 42 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Sep 23, 2026, 10:32 AM EDT
Withdrawn Phase 4 Interventional

Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus

NCT04697485
View directory record Official record
Conditions
HF - Heart Failure, Diabetes Mellitus
Interventions
Bumetanide 0.5 mg, dapaglifozin 5 mg, eplerenone 25 mg
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Sep 23, 2026, 10:32 AM EDT
Completed Not applicable Interventional Results available

Eplerenone for the Treatment of Central Serous Chorioretinopathy

NCT01990677
View directory record Official record
Conditions
Central Serous Chorioretinopathy
Interventions
25mg Eplerenone, Placebo
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
10
States / cities
Cherry Hill, New Jersey • Marlton, New Jersey • Mays Landing, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Sep 23, 2026, 10:32 AM EDT
Recruiting Phase 4 Interventional

Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study

NCT05030545
View directory record Official record
Conditions
Primary Aldosteronism, Hypertension
Interventions
Eplerenone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Sep 23, 2026, 10:32 AM EDT
Completed Phase 4 Interventional Results available

Diurnal Variation of Plasminogen Activator Inhibitor-1

NCT00515021
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
Eplerenone (Morning), Eplerenone (Night-time)
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Sep 23, 2026, 10:32 AM EDT
Completed No phase listed Observational

Glucose Metabolism in Subjects With Aldosterone-Producing Adenomas

NCT02362308
View directory record Official record
Conditions
Primary Aldosteronism
Interventions
Adrenalectomy, mineralocorticoid receptor antagonist
Other · Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Sep 23, 2026, 10:32 AM EDT
Terminated Not applicable Interventional

A Study of the Effects of Eplerenone and Amlodipine on Blood Pressure and Basal Metabolic Rate in Obese Hypertensives

NCT00825188
View directory record Official record
Conditions
Obesity, Hypertension
Interventions
eplerenone, amlodipine, eplerenone, amlodipine
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
21 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated May 28, 2018 · Synced Sep 23, 2026, 10:32 AM EDT
Completed Phase 1 Interventional

Treatment of Supine Hypertension in Autonomic Failure

NCT00223717
View directory record Official record
Conditions
Hypertension
Interventions
Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Placebo, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt., aliskiren, Local heat stress
Drug · Dietary Supplement · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Sep 23, 2026, 10:32 AM EDT
Completed Not applicable Interventional Results available

Eplerenone in HIV Associated Abdominal Fat Accumulation

NCT01405456
View directory record Official record
Conditions
HIV
Interventions
Eplerenone and lifestyle, placebo and lifestyle
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Sep 23, 2026, 10:32 AM EDT
Completed Not applicable Interventional

Aldosterone and Vascular Disease in Diabetes Mellitus

NCT00214825
View directory record Official record
Conditions
Diabetes Mellitus, Endothelial Dysfunction, Albuminuria
Interventions
eplerenone, Hydrochlorothiazide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 64 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 2, 2008 · Synced Sep 23, 2026, 10:32 AM EDT
Completed Phase 2 Interventional Results available

Eplerenone for Central Serous Chorioretinopathy

NCT01822561
View directory record Official record
Conditions
Central Serous Chorioretinopathy
Interventions
Eplerenone 50mg
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Sep 23, 2026, 10:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Eplerenone on Postprandial Inflammatory Response in Healthy Adults

NCT01786551
View directory record Official record
Conditions
Systemic Proinflammatory State
Interventions
Eplerenone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Sep 23, 2026, 10:32 AM EDT
Completed Phase 2 Interventional Results available

Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone

NCT01807221
View directory record Official record
Conditions
Heart Failure
Interventions
Finerenone (BAY94-8862), Placebo, Inspra (eplerenone)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2021 · Synced Sep 23, 2026, 10:32 AM EDT
Terminated Phase 2 Interventional Results available

Cardiometabolic Effects of Eplerenone in HIV Infection

NCT02629094
View directory record Official record
Conditions
Cardiac Steatosis, Hepatic Steatosis
Interventions
Inspra /Eplerenone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 23, 2026, 10:32 AM EDT
Recruiting Phase 3 Interventional

Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction

NCT02901184
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Spironolactone, Standard care
Drug · Other
Lead sponsor
Uppsala University
Other
Eligibility
50 Years to 99 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
38
States / cities
Alexander City, Alabama • Birmingham, Alabama • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Sep 23, 2026, 10:32 AM EDT
Completed Not applicable Interventional Results available

Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular Dystrophy

NCT01521546
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
eplerenone, placebo
Drug
Lead sponsor
Subha Raman
Other
Eligibility
7 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Los Angeles, California • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Sep 23, 2026, 10:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Mineralocorticoid Receptor (MR) Antagonist (Eplerenone) vs Amlodipine and STRIATIN

NCT03683069
View directory record Official record
Conditions
Hypertension, Genetics Hypertension
Interventions
Eplerenone vs Amlodipine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Sep 23, 2026, 10:32 AM EDT
Recruiting Phase 4 Interventional

Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension

NCT05593055
View directory record Official record
Conditions
Hypertension, Left Ventricular Hypertrophy
Interventions
Eplerenone, Chlorthalidone, Potassium
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 23, 2026, 10:32 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Eplerenone in the Treatment of Hypertension in Children.

NCT00147589
View directory record Official record
Conditions
Hypertension
Interventions
Eplerenone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
6 Years to 16 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
28
States / cities
Little Rock, Arkansas • Beverly Hills, California • Inglewood, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Sep 23, 2026, 10:32 AM EDT
Terminated Phase 4 Interventional

Reversing Endothelial and Diastolic Dysfunction and Improving Collagen Turnover in Diastolic Heart Failure

NCT00293150
View directory record Official record
Conditions
Diastolic Heart Failure
Interventions
Eplerenone
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Sep 23, 2026, 10:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects Of Eplerenone On Serum Aldesterone And Plasma Renin Activity

NCT00990223
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Eplerenone or Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
Miami, Florida • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Sep 23, 2026, 10:32 AM EDT
Completed No phase listed Observational

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

NCT04467931
View directory record Official record
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 23, 2026, 10:32 AM EDT